There are currently 28 active clinical trials seeking participants for Interstitial Lung Disease research studies. The states with the highest number of trials for Interstitial Lung Disease participants are California, Texas, Florida and New York.
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535
Recruiting
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: UAB Lung Health Center, Birmingham, Alabama +116 locations
Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Register for Updates
PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
NCT06855329
Recruiting
This is a prospective, observational cohort study. Participants with non-idiopatic pulmonary fibrosis, interstitial lung disease (ILD) will be followed for 24 months to systematically collect clinical, imaging, and biospecimen data. The primary objective is to optimize progressive pulmonary fibrosis (PPF) classification and establish PPF incidence for key ILD subtypes. Additional exploratory objectives are to 1) Prospectively validate a novel PPF classifier and assess performance durability over... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/12/2025
Locations: University of Massachusetts Chan Medical School, Worcester, Massachusetts +3 locations
Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Register for Updates
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
NCT06325696
Recruiting
Background: Interstitial lung disease affects the tissues that aid the transfer of oxygen and carbon dioxide between the air and the bloodstream. The disease can cause fibrosis, a thickening and scarring of lung tissue. Fibrosis often continues getting worse, and most people with this disease die in 3 to 5 years. Objective: To test a study drug (hymecromone) in people with interstitial lung disease or lung fibrosis. Eligibility: People aged 18 years and older with interstitial lung disease... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/07/2025
Locations: NIEHS Clinical Research Unit (CRU), Research Triangle Park, North Carolina
Conditions: Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Lung Diseases, Interstitial
Register for Updates
Collagen-targeted PET Imaging for Early Interstitial Lung Disease
NCT05417776
Recruiting
The goal of this study is to investigate the ability of \[68Ga\]CBP8 to detect collagen deposition in early interstitial lung disease.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
05/06/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Interstitial Lung Disease
Register for Updates
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
NCT05892614
Recruiting
This is a 2-Part study with Part A, a double-blind, randomized, placebo-controlled, PoC study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with SSc-ILD. The primary objective of the study is to evaluate the PoC for efficacy in a population with SSc-ILD. While improvement of ILD is the outcome of interest, the study will also evaluate changes in the skin. After initial screening (up to 4 weeks), approximately 25 eligible participants will be randomized 2:2:1 to 1... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: aTyr Investigative Site, Los Angeles, California +14 locations
Conditions: Interstitial Lung Disease
Register for Updates
Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)
NCT03478826
Recruiting
To develop a repository of blood samples from patients with ILD to support future studies into the development of such biomarkers. Patients with pneumonia and healthy patients will also be recruited as a control group.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Interstitial Lung Disease
Register for Updates
Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough
NCT05120934
Recruiting
This research study is evaluating the effectiveness of escalating doses of Amitriptyline and Duloxetine in reducing cough frequency in patients with interstitial lung disease (ILD)-related cough.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/18/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Interstitial Lung Disease
Register for Updates
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT06388421
Recruiting
This is a prospective, non-interventional, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: NCH Research Institute, Naples, Florida +10 locations
Conditions: Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
Register for Updates
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
NCT04624490
Recruiting
The purpose of this study is to develop and evaluate the usefulness of hyperpolarized (HP) 129Xe gas MRI for regional assessment of pulmonary function.
Gender:
ALL
Ages:
3 years and above
Trial Updated:
04/01/2025
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Hypertension, Pulmonary Infection, Other Lung Disease
Register for Updates
Autologous Stem Cell Transplantation in Patients with Systemic Sclerosis
NCT03630211
Recruiting
The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment effect.
Gender:
ALL
Ages:
Between 8 years and 60 years
Trial Updated:
03/13/2025
Locations: Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania +2 locations
Conditions: Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary Hypertension
Register for Updates
Feasibility of Semaglutide in Advanced Lung Disease
NCT05746039
Recruiting
The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question\[s\] it aims to answer are: 1. Are patients with advanced lung disease able to tolerate semaglutide therapy? 2. Are we able to titrate semaglutide therapy to a target weight? Participants will be asked to perform pulmonary function, physical function and body composition testing, as well as a bl... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/13/2025
Locations: University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
Conditions: Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary Hypertension
Register for Updates
Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection
NCT05776225
Recruiting
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Pulmonary Associates, Phoenix, Arizona +41 locations
Conditions: Interstitial Lung Disease, Pulmonary Hypertension
Register for Updates